为评估中国广州地区人乳头瘤病毒（HPV）基因型的患病率和特征以及其相关的宫颈病变情况，以有助于调整该地区特定于宫颈癌的预防和控制策略，共招募了58630名妇女。收集了宫颈标本进行HPV DNA检测和/或宫颈细胞学检查。对可见宫颈病变或异常筛查结果的患者进行进一步宫颈活检。整体HPV阳性率为14.07%。广州地区前五个基因型为HPV 52（3.06%）、HPV 16（2.28%）、HPV 58（1.80%）、HPV 51（1.32%）和HPV 39（1.15%）。从2016年到2019年，整体HPV和疫苗靶向HPV基因型的患病率呈显著下降趋势（P < 0.05）。然而，在此期间，HPV 35的感染率显著增加（P = 0.015）。任何HPV基因型的年龄特异性患病率呈双峰曲线，首先在< 20 岁年龄组达到峰值，然后在> 59 岁年龄组达到第二个峰值。在HPV阳性妇女中，高级宫颈上皮内病变（HSIL）和宫颈癌的比例随年龄的增加而显著增加（P < 0.05）。在> 59 岁年龄组中，9.35%的HPV阳性病例被诊断为宫颈癌。HPV 16/18是宫颈癌最常见的原因。然而，宫颈癌患者中非HPV 16/18感染的比例随时间增加，从2015年的15.21%增加到2019年的26.32%（P = 0.010）。此外，宫颈癌患者中非HPV 16/18基因型的患病率随年龄的增加显著增加，峰值出现在> 59 岁年龄组（P = 0.014）。尽管任何HPV和疫苗靶向HPV基因型的患病率随着时间的推移显著下降，但在大规模HPV疫苗普及后仍然重要跟踪HPV基因型及其相关的癌症风险。并且，在广州的宫颈癌筛查策略和基于风险的管理中应考虑年龄因素。版权所有 © 2023 作者。由Elsevier Ltd.发表。保留所有权利。

To assess the prevalence and characteristics of human papillomavirus (HPV) genotypes and its associated cervical lesions in Guangzhou, China, which may be useful for adjusting area-specific cervical cancer prevention and control strategies.A total of 58630 women were enrolled. Cervical specimens were collected for HPV DNA testing and/or cervical cytology. Patients with visible cervical lesions or abnormal screening results underwent further cervical biopsies.The overall HPV positive rate was 14.07%. The top five genotypes in Guangzhou were HPV 52 (3.06%), HPV 16 (2.28%), HPV 58 (1.80%), HPV 51 (1.32%), and HPV 39 (1.15%). The prevalence of overall HPV and vaccine-targeted HPV genotypes showed a significantly decreasing trend from 2016 to 2019 (P < 0.05). While, the infection rate of HPV 35 increased significantly during this time (P = 0.015). The age-specific prevalence of any HPV genotypes showed a bimodal curve, which peaked firstly among the < 20 y age group, and then peaked secondly among the > 59 y age group. Among HPV-positive women, the proportions of HSIL and cervical cancer increased significantly with age (P < 0.05). Among > 59 y age group, 9.35% HPV-positive cases were diagnosed as cervical cancer. HPV 16/18 was the most common cause of cervical cancer. While, the percentage of non-HPV 16/18 infection among cervical cancer patients increased over time, from 15.21% in 2015 to 26.32% in 2019 (P = 0.010). Besides that, the prevalence of non-HPV 16/18 genotypes among cervical cancer patients significantly increased with age, which peaked at the > 59 y age group (P = 0.014).Although the prevalence of any HPV and vaccine-targeted HPV genotypes decreased significantly with time, it is still important to follow the HPV genotypes and their associated cancer risk after the large-scale popularization of HPV vaccine. And age should be taken into consideration in screening strategies and risk-based management of cervical cancer in Guangzhou.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.